EGFR and neoplasm: In triple-negative breast cancers (TBNCs), which are very aggressive tumors characterized by the lack of ER, progesterone receptor (PR), and HER2, high expression and reciprocal compensation between β1 integrin and EGFR signaling synergize to support tumor progression and metastasis48.